Key Highlights

  • Product Revenue of USD 524.4 million beat the consensus estimate of USD 500.36 million, against USD 142.3 million last year.
  • Loss per share of USD 0.46 was wider than the consensus estimate of USD 0.38 but narrowed from USD 1.75.
  • BRINSUPRI generated USD 400.1 million, up 29% sequentially, while ARIKAYCE added USD 124.4 million, up 9% year over year.
  • BRINSUPRI full year guidance is USD 1.35 billion to USD 1.4 billion, with cash and securities near USD 1.1 billion.

Insmed Incorporated (NASDAQ:INSM) reported third quarter 2026 net product revenue of USD 524.4 million, ahead of the consensus estimate of USD 500.36 million and well above USD 142.3 million in the same period of 2025. The net loss per share was USD 0.46, wider than the consensus estimate of a loss of USD 0.38, though much improved from a loss of USD 1.75 a year earlier. Net loss was USD 100.3 million compared with USD 370.0 million, and the operating loss narrowed to USD 89.4 million from USD 366.0 million.

Launch Economics and Expense Growth

BRINSUPRI contributed USD 400.1 million, a 29% sequential increase, and Chair and CEO Will Lewis said the product passed USD 1 billion of revenue within its first four full quarters of launch. ARIKAYCE revenue was USD 124.4 million. Cost of product revenues was USD 78.2 million, or 14.9% of revenue, compared with 20.6% a year earlier.

Spending climbed alongside the launch. Research and Development reached USD 270.0 million and selling, general and administrative expense was USD 253.0 million, and the chief financial officer said the two combined rose 40% from the prior year. The quarter also included a USD 7.5 million increase in the Fair Value of contingent consideration, versus USD 104.7 million a year earlier.

Guidance and Pipeline Commentary

The company raised the low end of its 2026 revenue guidance for both products. BRINSUPRI is now guided to USD 1.35 billion to USD 1.4 billion, a USD 50 million lift at the midpoint, and ARIKAYCE to USD 460 million to USD 470 million. Gross to net guidance was reiterated at mid to high 20s for BRINSUPRI and low to mid 20s for ARIKAYCE. Under the small manufacturer phase in, the company covers 5% of catastrophic Medicare costs on ARIKAYCE in 2027, rising annually to 20% in 2031.

Mr. Lewis said Japan launched BRINSUPRI 25 milligram tablets last week, with roughly 150,000 diagnosed bronchiectasis patients there. The company cited a peak sales estimate above USD 7 billion for BRINSUPRI and above USD 6 billion for TPIP, which has four phase III trials running. Management reported a clear line of sight to Cash Flow positivity in 2027.

Dates and Metrics Ahead

Several items are scheduled or quantified. A first branded television campaign for BRINSUPRI starts next month, and management said it typically provides product guidance around the January investor conference. TPIP phase III enrollment is slated to complete by the first half of 2028 at the latest, with the interstitial lung disease study described as about six months ahead of schedule.

The company also flagged possible 2027 label expansions for ARIKAYCE in the U.S. and Japan, new phase II starts in 2027 for INS1033 and INS1148, and gene therapy data in DMD and ALS in 2027. Cash, equivalents and marketable securities stood near USD 1.1 billion, and the chief financial officer announced a planned departure on the call.